Camp4 Therapeutics is a Watertown, Massachusetts-based clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, and the company is in the middle of a fiscal second quarter that demonstrates the kind of clinical-development pivot the regulatory-RNA biotech cohort has been waiting for. Q2 2026 net loss of $33.5 million was 166.3 percent above the prior-year quarter's $12.6 million, with the increase primarily driven by a $20.9 million non-cash loss recognized due to a change in fair value of the derivative tranche liability related to the September 2025 private placement. The cash position of $86.4 million at quarter-end, combined with the $50.1 million in gross proceeds from the second closing of the private placement, extends the cash runway through the end of 2028. The combination of the regulatory clearance for the CMP-002 Phase 1/2 trial in Australia and Argentina, the cash runway extension through the end of 2028, and the upcoming Virtual Analyst Day on September 28, 2026 is the cleanest single-sentence read on what the regulatory-RNA biotech business model is producing, and the combination is the source of the platform-validation profile the equity offers the buy-side.
The numbers tell the story with the kind of operational detail the regulatory-RNA biotech equity has been waiting for. The Q2 2026 R&D expense of $10.8 million was 4.6 percent above the prior-year quarter's $10.3 million, with the expenses primarily driven by clinical and preclinical study costs. The H1 2026 R&D expense of $21.0 million was 2.4 percent above the prior-year period's $20.5 million. The Q2 2026 G&A expense of $4.3 million was 3.8 percent above the prior-year quarter's $4.2 million, with the increase primarily driven by an increase in stock-based compensation expense.
The H1 2026 net loss of $51.9 million was 107.3 percent above the prior-year period's $25.0 million, with the H1 2026 net loss including the $20.9 million non-cash loss from the change in fair value of the derivative tranche liability. The H1 2026 net loss per share of $0.90 was 27.4 percent above the prior-year period's $1.24, with the per-share loss improvement reflecting the share count increase from 20.2 million in the prior-year quarter to 57.9 million in the most recent quarter.
The question the next four quarters resolve is whether the company can initiate the CMP-002 Phase 1/2 trial in Q4 2026 and produce a meaningful clinical-data disclosure, and whether the cash runway through the end of 2028 is sufficient to fund the clinical-development advancement. A Q4 2026 update that announces the CMP-002 Phase 1/2 trial initiation would confirm the platform-validation profile is producing, with the resulting clinical-data disclosure positioning the company as a regulatory-RNA biotech commercial entity. A Q4 2026 update that shows the trial initiation delayed or the clinical-data disclosure delayed would force the market to reprice the equity for a more modest terminal value.